We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

用无创尿检检测前列腺癌

By LabMedica International staff writers
Posted on 17 Apr 2018
Print article
CellDetect平台是唯一能在形态检查的同时区分正常细胞、癌变前细胞与癌细胞颜色的组织化学解决方案(图片蒙Micromedic Technologies公司惠赐)。
CellDetect平台是唯一能在形态检查的同时区分正常细胞、癌变前细胞与癌细胞颜色的组织化学解决方案(图片蒙Micromedic Technologies公司惠赐)。

前列腺癌是世界上男性第二常见的癌症。大概每九个男子中就有一人在一生中被诊断出前列腺癌。据估计,2018年美国将有约165千例前列腺癌新发病例,致死约29,000例。

 

前列腺癌原先通过直肠指检诊断,如果医生发现前列腺组织、形状或大小的任何异常,就需要让患者做进一步检验。前列腺特异抗原(PSA)检验被用来分析血样中是否有前列腺自然产生的一种物质。

 

以色列雷霍沃特市开普兰医疗中心的科学家开展的一项临床研究包括59份尿样(来自28名前列腺癌阳性患者与31名健康对照者),一名细胞病理学家用以色列特拉维夫Micromedic Technologies公司CellDetect独一颜色标记物检查过这些样本。CellDetect是新一代细胞病理染色平台,可准确检测癌症。它基于颜色与形态的独特组合提供专利型诊断解决方案。多项临床研究已证明CellDetect检测宫颈癌与膀胱癌的效力,据估计,这项技术还可用于检测别的癌症。

 

科研小组发现,所检验的59份样本中,高达80%得到明确诊断并相应出现在临床研究结果中。比较前列腺癌阳性患者的结果与临床研究前这些患者的活检结果。结果表明Micromedic公司的产品成功检测到尿样中的前列腺癌细胞,灵敏度高达91.3%,特异性为75%

 

Micromedic公司CEO、工商管理硕士Guy Lerner说:这项临床研究的结果令我们非常高兴,它说明CellDetect技术有望显著改进前列腺癌的诊断。虽然前列腺癌是世界上男性第二常见的癌症,但是我们知道现有的诊断检验不可靠。有了这些临床研究的结果,我们确信我们的产品有望颠覆前列腺癌诊断,为患者提供一种准确可靠的无创检验,通过节省可观的医疗费改良卫生系统。


Related Links:
开普兰医疗中心>>> www.clalit-global.co.il
Micromedic Technologies >>> www.m-medic.com

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more